Blocker of IKur
ultrarapid delayed rectifier potassium current and KV
1.5 channels (IC50
= 0.31 μ
M for rKV
1.5). Displays selectivity for inhibition of IKur
(20-fold) in native myocytes and selectivity for rat recombinant KV
1.5 over KV
3.1 (~ 15-fold). Increases action potential duration in atrial but not ventricular myocytes and prevents atrial arrhythmia.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide.
Stump et al.
In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.
Regan et al.
Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapid activating delayed rectifier potassium current.
Lagrutta et al.
The citations listed below are publications that use Tocris products. Selected citations for DPO-1 include:
Showing Results 1 - 3 of 3